Abstract
Public demand for totally safe drugs has led to excessive, costly and misleading toxicity testing. Such testing drains the resources which have been available for discovering much needed new drugs. Better public understanding of the limitations of toxicity testing and the hazards of medication is sorely needed in order to improve the prospects for diseases still needing effective treatments.
Article PDF
References
Nature 283, 609 (1980).
Br. med. J. ii, 670 (1980).
Steward, F. & Wibberley, G. Nature 284, 118 (1980).
Cromie, B. W. Br. med. J. i, 1618–1619 (1978).
Wardell, W. M., Dihaddo, J. & Trimble, A. G. Clin. Pharmac. Ther. 28, 270–277 (1980).
Newbould, B. B. in Risk-Benefit Analysis in Drug Research (ed. Cavalla, J. F.) 17–25 (MTP Press, Lancaster, 1981).
Walshe, J. M. Br. med. J. ii, 710–702, (1975).
Lasagna, L. Regulation 3, 27–32 (1979).
Cavalla, J. F. Br. med. J. i, 1486 (1978).
Black, D. in Risk-Benefit Analysis in Drug Research (ed. Cavalla, J. F.) 179–184 (MTP Press, Lancaster, 1981).
Gross, F. Acta pharm. suecica 10, 401 (1973).
Beeson, P. Medicine, Baltimore 59, 79–99 (1980).
Kinlen, L.J., Sheil, A.G.R., Peto, J. & Doll, R. Br. med. J. ii, 1461–1466 (1979).
Wardell, W. M. Clin. Pharmac. Ther. 15, 73–96 (1974).
de Maar, E. W. J. Trans. R. Soc. trap. Med. Hyg. 73, 147–149 (1979).
Hornykiewiez, O. Br. med. Bull. 29, 172–178 (1973).
Stastny, P. J. clin. Invest. 57, 1148–1157 (1976).
Panayi, G.S., Wooley, P. & Batchelor, J.R. Br. med. J. ii, 1326–1328 (1979).
Batchelor, J. R., Compston, A. & McDonald, W. I. Br. med. Bull. 34, 279–284 (1978).
Dunlop, D. J. R. Soc. Med. 73, 405–407 (1980).
Goldberg, L. Perspectives Biol. Med. 21, 167–195 (1979).
Hitchings, G. H. Cancer Res. 29, 1895–1903 (1969).
Eur. J. clin. Pharmac. 11, 233–238 (1978).
Meade, T. W. Br. J. prev. soc. Med. 29, 157–169 (1975).
Kirby, T. J. Trans. Am. Ophth. Soc. 65, 494–543 (1967).
Wright, P. Br. med. J. i, 595–598 (1975).
Levy, M. & David, D. Int. J. clin. Pharmac. 16, 479–481 (1978).
Amsler, H. A., Teerenhovi, L., Barth, E., Harjula, K. & Vuopio, P. Acta psychiatr. scand. 56, 241–248 (1977).
Anderman, B. & Griffith, R. W. Eur. J. clin. Pharmac. 11, 199–201 (1977).
Kalow, W. Anaesthetist 15, 13–18 (1966).
Fraser, I. M. & Vesell, E. S. Ann. N.Y. Acad. Sci. 151, 777–794 (1968).
Batchelor, J. R. et al. Lancet i, 1107–1109 (1980).
Litchfield, J. T. J. Am. med. Ass. 177, 104–108 (1961).
Barnes, J. M. Proc. Eur. Soc. Study Drug Toxic. ii, 57–64 (1963).
Modell, W. in Drug Responses in Man (eds Wolstenholme, G. & Porter, R.) 247–249 (Churchill, London, 1967).
Fletcher, A. P. J. R. Soc. Med. 71, 693–696 (1978).
Mitchell, J. R., Potter, W. Z., Hinson, J. A. & Jollow, D. J. Nature 251, 508–510 (1974).
Mitchell, J. R., Nelson, W. L., Potter, W. Z., Sasame, H. A. & Jollow, D. J. J. Pharmac. exp. Ther. 199, 41–52 (1976).
Smith, C. G., Poutsiaka, J. W. & Schreiber, E. C. J. int. med. Res. i, 489–503 (1973).
Richmond, H. G. Br. med. J. i, 947 (1959).
Haddow, A., Roe, F. J. C. & Mitchley, B. C. V. Br. med. J. i, 1593–1594 (1964).
Grasso, P. & Golberg, L. Food Cosmet. Tox. 4, 297–320 (1966).
Weinbren, K. Br. med. J. i, 683–685 (1978).
Gilette, R. J. in Drug Metabolism (eds Parke, D. V. & Smith, R. L.) 147–186 (Taylor and Francis, London, 1976).
First Report of the Expert Committee on Drug Toxicity ( Association of the British Pharmaceutical Industry, London, 1964).
Long Term Toxic Effects, a Study Group Report (The Royal Society, London, 1978).
Ashby, J. & Styles, J. A. Nature 274, 20–21 (1978).
Ames, B. & Hooper, K. Nature 274, 19–20 (1978).
Maher, V. M. & McCormick, J. J. in Chemical Carcinogens and DNA Vol. 2 (ed. Grover, P. L.) 133–158 (CRC Press, Boca Raton, Florida, 1979).
Jukes, T. H. Clin. Tox. 14, 133–139 (1979).
Schupbach, M. E. Mutat. Res. 68, 41–49 (1979).
Nagao, M., Takahashi, Y., Yamanaka, H. & Sugimara, T. Mutat. Res. 68, 101–106 (1979).
Gruener, N. & Lockwood, M. P. Am. J. pub. Hlth 70, 276–278 (1980).
Kelly, M. & Baden, J. M. Mutat. Res. 77, 185–188 (1980).
Wolfe, W. G. A. Rev. Med. 26, 203–217 (1975).
Ashton, N. Am. J. Ophthal. 62, 412–435 (1966).
MacMahon, B., Ven, S., Trichopoulos, D., Warren, K. & Nardi, G. New Engl. J. Med. 304, 630–633 (1981).
Cuatrecasas, P. Science 203, 6–7 (1979).
Hartley-Asp, B. Lancet i, 981 (1979).
Hartley-Asp, B. Mutat. Res. 67, 193–196 (1979).
Hartley-Asp, B. Tox. Lett. 4, 15–19 (1979).
Pharm. J. 224, 493, 505 (1980) 226, 417 (1981).
Venning, G. R. Br. med. J. 284, 249–254 (1982).
Vere, D. W. Proc. R. Soc. Med. 69, 105–107 (1976).
Dollery, C. T. & Rawlins, M. D. Br. med. J. i, 96–97 (1977).
Inman, W. H. W. Br. med. J. 282, 1131–1132, 1216–1217 (1981).
Griffin, J. P. & Diggle, G. E. Br. J. clin. Pharmac. 12, 453–463 (1981).
Mole, R. H. Proc. R. Soc. Med. 69, 107–113 (1976).
Lee, T. R. Proc. R. Soc. A316, 5–16 (1981).
Wardell, W. M. Clin. Pharmac. Ther. 24, 499–524 (1978).
Wardell, W. M. Regulation 3, 25–33 (1979).
Shubin, S. Perspectives Biol. Med. 22, 185–204 (1979).
Hanley, T., Udall, V. & Weatherall, M. Br. med. Bull. 26, 203–207 (1970).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Weatherall, M. An end to the search for new drugs?. Nature 296, 387–390 (1982). https://doi.org/10.1038/296387a0
Issue Date:
DOI: https://doi.org/10.1038/296387a0
This article is cited by
-
Animal models and conserved processes
Theoretical Biology and Medical Modelling (2012)
-
Diagnosing the decline in pharmaceutical R&D efficiency
Nature Reviews Drug Discovery (2012)
-
Too many drugs?
Nature (1982)
-
The role of the pharmaceutical industry in diabetes research
Diabetologia (1982)